Skip to main content
. 2017 Nov 27;22(12):2070. doi: 10.3390/molecules22122070

Table 1.

Summary of different Cell-SELEX experiments performed in the last few years.

Aptamer Method Target Cell Kd (nM) Reference
RNA Cell-SELEX HER-2-overexpressing breast cancer 94.6 [43]
DNA Cell-SELEX Acute myeloid leukemia cells 5.4 ± 1.6 [35]
RNA Cell-SELEX Mouse embryonic stem cells - [54]
DNA Cell-SELEX Human hepatocarcinoma 19–450 [55]
RNA Cell-SELEX AC133-epitope of CD133 expressed on HEK293T cells 33.85–145 [34]
DNA Cell-SELEX Over-expressing epidermal growth factor receptor variant III on human glioblastoma ≤100 [56]
DNA on-chip Cell-SELEX Different histologically classified ovarian cancer cells 1.3 [57]
DNA Cell-SELEX Epidermal growth factor receptor variant III on Glioblastoma 3.37 ± 0.98 [58]
DNA Cell-SELEX Metastatic colorectal cell 8.1 ± 0.9 [59]
DNA Cell-SELEX Prostate cancer cells 73.59 ± 11.01 [60]
RNA Cell-SELEX Annexin A2 10.5 ± 4.6 [61]
DNA Cell-SELEX By flow cytometry 3T3-L1 adipocytes cells 33.1 ± 2.9 [62]
RNA Cell-SELEX PC3-prostate cancer cell 71.57 ± 12.96 [63]
DNA Cell-SELEX Human hepatoma cells HepG2 64–349 [64]
DNA On-chip Cell-SELEX Colorectal cancer cells 12.3 [65]
DNA Cell-SELEX Hepatocellular carcinoma 9.4 ± 2.0 [66]
DNA Cell internalization SELEX MCF10CA1h human breast ductal carcinoma [67]
DNA Cell-SELEX Nasopharyngeal carcinoma cell lines 11.93 ± 1.40 [68]
DNA Cell-SELEX Renal cell carcinoma (768-O) 9.4 ± 2.0 [69]
DNA Cell-SELEX Metastatic colorectal carcinoma LOVO cells 167.3 ± 30.2 [70]